These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 7726523)
21. Grepafloxacin--a new fluoroquinolone. Med Lett Drugs Ther; 1998 Jan; 40(1019):17-8. PubMed ID: 9465856 [No Abstract] [Full Text] [Related]
22. Single-dose pharmacokinetics and penetration of BMS 284756 into an inflammatory exudate. Wise R; Gee T; Marshall G; Andrews JM Antimicrob Agents Chemother; 2002 Jan; 46(1):242-4. PubMed ID: 11751144 [TBL] [Abstract][Full Text] [Related]
23. The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects. Bron NJ; Dorr MB; Mant TG; Webb CL; Vassos AB J Antimicrob Chemother; 1996 Dec; 38(6):1023-9. PubMed ID: 9023649 [TBL] [Abstract][Full Text] [Related]
24. Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables. Tran JQ; Ballow CH; Forrest A; Hyatt JM; Sands MF; Peloquin CA; Schentag JJ J Antimicrob Chemother; 2000 Mar; 45():9-17. PubMed ID: 10719007 [TBL] [Abstract][Full Text] [Related]
25. Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. Cook PJ; Andrews JM; Wise R; Honeybourne D; Moudgil H J Antimicrob Chemother; 1995 Feb; 35(2):317-26. PubMed ID: 7759395 [TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and inflammatory fluid penetration of cefpodoxime proxetil in volunteers. O'Neill P; Nye K; Douce G; Andrews J; Wise R Antimicrob Agents Chemother; 1990 Feb; 34(2):232-4. PubMed ID: 2327771 [TBL] [Abstract][Full Text] [Related]
27. Tissue penetration and pharmacokinetics of lomefloxacin following multiple doses. Kavi J; Stone J; Andrews JM; Ashby JP; Wise R Eur J Clin Microbiol Infect Dis; 1989 Feb; 8(2):168-70. PubMed ID: 2498102 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Nakashima M; Uematsu T; Kosuge K; Umemura K; Hakusui H; Tanaka M Antimicrob Agents Chemother; 1995 Jan; 39(1):170-4. PubMed ID: 7695301 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. Forrest A; Chodosh S; Amantea MA; Collins DA; Schentag JJ J Antimicrob Chemother; 1997 Dec; 40 Suppl A():45-57. PubMed ID: 9484873 [TBL] [Abstract][Full Text] [Related]
30. Transplacental pharmacokinetics of the new fluoroquinolone DW-116 in pregnant rats. Kim JC; Bae CS; Kim SH; Yun HI; Park SC; Shin HC; Han J; Chung MK Toxicol Lett; 2003 Apr; 142(1-2):103-9. PubMed ID: 12765244 [TBL] [Abstract][Full Text] [Related]
31. Penetration of moxifloxacin into peripheral compartments in humans. Müller M; Stass H; Brunner M; Möller JG; Lackner E; Eichler HG Antimicrob Agents Chemother; 1999 Oct; 43(10):2345-9. PubMed ID: 10508004 [TBL] [Abstract][Full Text] [Related]
32. Penetration of temafloxacin into body tissues and fluids. Sörgel F Clin Pharmacokinet; 1992; 22 Suppl 1():57-63. PubMed ID: 1319872 [TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of rufloxacin in healthy volunteers after repeated oral doses. Mattina R; Bonfiglio G; Cocuzza CE; Gulisano G; Cesana M; Imbimbo BP Chemotherapy; 1991; 37(6):389-97. PubMed ID: 1662127 [TBL] [Abstract][Full Text] [Related]
34. Safety, tolerability and pharmacokinetics of the new long-acting quinolone DW-116 after single and multiple dosing in healthy subjects. Meyerhoff C; Dilger C; Yoon SJ; Chung YH; Lee DK; Lee CW; Ryu JM; Choi MS; Pabst G; Reh C J Antimicrob Chemother; 1998 Sep; 42(3):349-61. PubMed ID: 9786475 [TBL] [Abstract][Full Text] [Related]
35. A comparative study of the repeat dose toxicity of grepafloxacin and a number of other fluoroquinolones in rats. Takizawa T; Hasimoto K; Itoh N; Yamashita S; Owen K Hum Exp Toxicol; 1999 Jan; 18(1):38-45. PubMed ID: 10025367 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. Nakashima M; Uematsu T; Kosuge K; Okuyama Y; Morino A; Ozaki M; Takebe Y J Clin Pharmacol; 1994 Sep; 34(9):930-7. PubMed ID: 7983237 [TBL] [Abstract][Full Text] [Related]
37. Gallbladder tissue concentrations, biliary excretion and pharmacokinetics of OPC-17116. Tanimura H; Uchiyama K; Kashiwagi H Drugs; 1995; 49 Suppl 2():341-3. PubMed ID: 8549355 [No Abstract] [Full Text] [Related]
38. Accumulation of a newly developed fluoroquinolone, OPC-17116, by human polymorphonuclear leukocytes. Taira K; Koga H; Kohno S Antimicrob Agents Chemother; 1993 Sep; 37(9):1877-81. PubMed ID: 8239600 [TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Wise R; Andrews JM; Marshall G; Hartman G Antimicrob Agents Chemother; 1999 Jun; 43(6):1508-10. PubMed ID: 10348784 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and urinary excretion of DW116, a new fluoroquinolone antibacterial agent, in humans as a phase I study. Jung BH; Choi MH; Chung BC Drug Dev Ind Pharm; 2000 Jan; 26(1):103-6. PubMed ID: 10677817 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]